SUBSCRIBE
SUBSCRIBE
News   Business

ErgoMed Signs Co-Development Deal With CeNeS Pharmaceuticals PLC

July 13, 2006 | 
1 min read

Ergomed today announced that it has signed a co-development deal with CeNeS Pharmaceuticals to take CNS5161, a novel NMDA antagonist, into a Phase II trial programme for neuropathic pain. Terms of the deal were not disclosed.

Alliances Clinical research Phase II Europe
MORE ON THIS TOPIC
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Cellectar Downsizes by 60% as it Explores Strategic Options for Cancer Drug
December 11, 2024
 · 
202 min read
 · 
BioSpace Editorial Staff
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
CAR-T
J&J, Legend Shrug Off Carvykti’s Challengers With New Phase III Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
Breast cancer
BioNTech Builds Case for PD-L1/VEGF Bispecific With Promising Breast Cancer Data
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
RSV
Moderna’s RSV Vaccines Run Into Safety Roadblock
December 11, 2024
 · 
2 min read
 · 
Tristan Manalac